Xeltis raises $34m for regenerative heart valve tech

Xeltis says it raised a $34 million Series B round for its technology to regenerate coronary valves and vessels.

Xeltis said today that it closed an over-subscribed Series B round worth about $34 billion for the regenerative heart valve technology it's developing.

Kurma Partners, Life Sciences Partners, VI Partners, Xeltis

News Well, Funding Roundup, Regenerative Medicine, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1wkBVGz